January 12, 2026, Originally posted to Business Wire Highlights: Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children […]
Press release originally posted to Business Wire on Thursday, Jan. 8, 2026 at 8:00am. – Company to present at J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 – SAN […]
− First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor cells (UMPCs) − The Phase 1/2a study will evaluate the safety and preliminary efficacy of […]
FOCUS will unify clinical trial, natural history, and patient data By Dr. Lucienne Ronco, FSHD Society As part of the Global FSHD Innovation Hub, the FSHD Society has undertaken the […]
No Time to Wait By Erin Saxon, FSHD Society Those living with FSHD face a harsh reality: this is a relentlessly progressive disease with no treatments to slow or stop […]
English English 
العربية
Español de México
Français du Canada
简体中文
